Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond

Current Oncology

View Publication Info
 
 
Field Value
 
Title Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond
 
Creator Amaro, C.P.
Tam, V.C.
 
Subject hepatocellular carcinoma
Sequencing
Second-line
Third-line
 
Description  
  Hepatocellular carcinoma (hcc) is one of the most common cancers in the world. It has a high mortality rate, espe­cially when localized treatments fail. For about a decade, the only systemic treatment shown to improve survival was sorafenib. Recently, lenvatinib was found to be noninferior to sorafenib for overall survival and the combination atezolizumab–bevacizumab improved survival compared with sorafenib. Similarly, in the post-sorafenib setting, a number of recent positive clinical trials have been reported, and they indicate that regorafenib, cabozantinib, and ramucirumab are effective and safe in the second-line setting.  
  With so many new options available, including immunotherapy, it is challenging to define the best sequence of systemic treatment for patients with hcc. In the present review, we introduce the current data for second-line sys­temic treatment and beyond in hcc. A treatment algorithm is also suggested, based on the best available evidence and expert opinion.
 
Publisher Multimed Inc.
 
Date 2020-08-04
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/7103
10.3747/co.27.7103
 
Source Current Oncology; Vol. 27 No. S3 (2020): Evolving Treatment Landscape of Hepatocellular Carcinoma: more choices, more responsibility
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/7103/9551
http://www.current-oncology.com/index.php/oncology/article/view/7103/9583
 
Rights Copyright (c) 2020 Multimed Inc.
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library